Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

microbiome SER-401

A donor-derived microbiome therapeutic composed of a combination of as of yet not disclosed microbes that were specifically selected to incorporate the bacterial signature found in melanoma patients who have a robust response to immunotherapy, with potential immunomodulating activity. Upon administration, SER-401 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tact and may re-establish a healthy microbiome in the GI tract. This may enhance a patient's immunological activity and improve a patient's response to immunotherapy.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	microbiome-based therapeutic SER-401
Code name:	SER 401 SER-401 SER401

microbiome SER-401

Search NCI's Drug Dictionary